Key statistics
On Tuesday, Mink Therapeutics Inc (INKT:NAQ) closed at 11.18, 76.34% above the 52 week low of 6.34 set on May 12, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 11.03 |
|---|---|
| High | 11.18 |
| Low | 10.96 |
| Bid | 10.99 |
| Offer | 11.38 |
| Previous close | 11.04 |
| Average volume | 6.34k |
|---|---|
| Shares outstanding | 4.69m |
| Free float | 1.68m |
| P/E (TTM) | -- |
| Market cap | 51.82m USD |
| EPS (TTM) | -3.03 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 20:59 GMT.
More ▼
Announcements
- MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
- MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
- MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
- MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
- MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
- MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
- MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
- MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
- MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
- MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
More ▼
